Atopic Dermatitis (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Atopic dermatitis (AD) is a chronic inflammatory skin disease of multifactorial etiology characterized by age-specific skin lesions, xerosis, and highly pruritic outbreaks. Usually starting in early childhood, AD significantly reduces patients’ quality of life. Patients with AD are more susceptible to developing allergic diseases and frequently suffer from multimorbidity. Multiple studies link AD during infancy to the future appearance of asthma and allergic rhinitis, with 80% of patients eventually developing either of them or both. Food allergies occur in 35% of children with AD, and cutaneous infections and keratoconjunctivitis are more frequent than in the general population.

·       According to the Thelansis research, atopic dermatitis (AD) globally affects 15%–20% of children and 1%–3% of adults. These prevalence figures are growing worldwide and show clear geographical variances; AD is more frequent in industrialized and high-income countries than in agriculture-based ones with low incomes.

·       The most frequent chronic comorbidities in children with AD of all ages and for both sexes were asthma (13.1%), psychosocial disorders (7.9%), visual impairment (7.8%), congenital anomalies of limbs (5.8%), and developmental disorders (3.2%), among others. All these comorbidities were more prevalent in the population with AD. Upper respiratory tract infections (54.4%), otitis media (12.8%), conjunctivitis (10.1%), and pharyngitis (7.9%) were amongst the most prevalent acute conditions in this atopic cohort.

Thelansis’s “Atopic Dermatitis (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atopic Dermatitis (AD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Atopic Dermatitis (AD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Atopic Dermatitis (AD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Atopic Dermatitis (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033